Re: Pharmacovigilance in India - Guidance on Clinical Trial SAE

[Guest guest]

Hello Manoj

I would ike to congratulate you for your posts on Pharmacovigilance in India.To

take up a topic expempore is really commendable.Further I would like to add that

though DCGI has become vigilant more strict vigilance on this pharmacovigilance

program is required.A fixed and heavy compensation (10 lakhs or more) should be

demanded in case of death of any participant in a clinical trial so that the

companies do not take this lightly.The pharmaceutical companies must realise

that compensation can in no way bring back the lost one and that Indians are no

guinea pigs. If a drug is being tested in India it must be provided in the

Indian Market at approachable rates after all the drug stands in the market

today because of these Indian participants.

Thank you so much for the information

Regards

Aditi Chaturvedi

> > > > > >

> > > > > > Hello,

> > > > > > The next discussion will run from 26-29 Aug 2011 on " ADR

Monitoring "

> > > > > which will

> > > > > > be moderated by Dr Gitanjali Kothiyal.

> > > > > > Welcome Dr.Geetanjali and please take over Netrum from 25th

> > > > > Aug.evening.Please

> > > > > > introduce your self before starting the discussion.

> > > > > > Kunda Gharpure

> > > > > >

> > > > >

> > > > >

> > > > >

> > > >

> > > >

> > > >

> > > > --

> > > > Dr.Manoj Swaminathan MBBS, MPH

> > > >

> > >

> >

>